12月10日 - ** 药物开发商 GRI Bio GRI.O 的股价在盘后交易中上涨 18% 至 1.43 美元
** 该公司称其试验性药物GRI-0621在治疗特发性肺纤维化的中期临床试验中显示出良好效果
** 该公司称，特发性肺纤维化是一种慢性肺病，治疗方法有限
** 近 40% 接受治疗的患者肺活量有所改善，而服用安慰剂的患者肺活量下降了 80% - GRI
** 试验招募了 35 名患者，其中大多数正在服用现有的 IPF 药物；血液检测显示肺部瘢痕减少 - GRI
** 包括本交易日的走势在内，该股今年累计下跌约 91
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.